Orexo’s development programs spans various delivery routes. Intranasal delivery offers significant advantages, and spray-dried amorphous powders with tightly controlled particle-size distribution support high nasal deposition while minimizing lung exposure.
AmorphOX is a powder-based drug delivery technology that stabilizes amorphous materials - such as peptides and biologics - and is designed to support strong bioavailability, enabling next-generation drug development.
Innovation drives Orexo’s mission, enabling advanced drug‑formulation solutions through cross‑disciplinary collaboration to address unmet global medical needs.
The OX390 program demonstrated positive data from a preclinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology. OX390 is developed in partnership with BARDA, which is part of the US Department of Health and Human Service.
Orexo and SVF Vaccines are collaborating to develop an **AmorphOX® powder formulation** for **LNP-mRNA vaccines**, targeting enhanced stability and storage solutions. The partnership focuses on research in **Sweden**, with potential applications for needle-free administration. The goal is to address logistical challenges in vaccine distribution and preservation.
Orexo reports progress in its platform shift during Q3 2026, though the company’s net losses widen. The company highlights advancements in its strategic transition while acknowledging financial challenges. Investors observe mixed signals as Orexo balances growth initiatives against increasing operational costs.
Orexo AB restructures its management team and organizational setup to prioritize advancing its development programs and AmorphOX® technology. The shift follows the divestment of Zubsolv® in the US market, redirecting resources toward innovation and new product pipelines. The company aims to strengthen its focus on research and commercialization efforts.
Orexo AB acquires full U.S. rights to **Zubsolv**, a buprenorphine/naloxone sublingual tablet for opioid use disorder, from Dexcel Pharma USA. The deal follows a previously signed asset purchase agreement. Zubsolv is classified as a Schedule III controlled substance under U.S. regulations.
Orexo partners with Abera to develop nasal powder vaccines using its **AmorphOX** technology. The collaboration focuses on stabilizing active ingredients and enabling alternative drug delivery methods, including nasal administration. AmorphOX-based formulations support a broad range of active ingredients, from small molecules to peptides.